Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.52 |
| ▸ | RXRA | P19793 | 3/20 | 0.50 |
| ▸ | RXRB | P28702 | 3/20 | 0.50 |
| ▸ | RXRG | P48443 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8014805 | 0.90 | LMNA (0.44) | MRGPRX4RXRARXRBRXRGLMNA | |
| SCHEMBL16098900 | 0.88 | MRGPRX4 (0.52) | MRGPRX4RXRARXRBRXRGLMNA | |
| SCHEMBL16097621 | 0.88 | LMNA (0.52) | MRGPRX4RXRARXRBRXRGLMNA | |
| SCHEMBL7953912 | 0.87 | MRGPRX4 (0.56) | MRGPRX4RXRARXRBRXRGLMNA | |
| SCHEMBL24817920 | 0.84 | NPC1 (0.50) | MRGPRX4RXRARXRBRXRGLMNA | |
| SCHEMBL8014807 | 0.83 | LMNA (0.44) | MRGPRX4RXRARXRBRXRGLMNA | |
| SCHEMBL16096150 | 0.83 | MRGPRX4 (0.47) | MRGPRX4RXRARXRBRXRGLMNA | |
| SCHEMBL3901040 | 0.82 | MRGPRX4 (0.60) | MRGPRX4RXRARXRBRXRGLMNA | |
| SCHEMBL3901919 | 0.82 | MRGPRX4 (0.69) | MRGPRX4RXRARXRBRXRGLMNA | |
| Hydrochloric Acid SCHEMBL7799879 | 0.81 | RXRA (0.44) | MRGPRX4RXRARXRBRXRGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2321274-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
| CN-1097579-C | Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament, and medicament comprising them | HOECHST AG (DE) | 2003-01-01 | — | — | CN | disclosed |
| US-6262123-B1 | AS ANTIARRHYTHMIC AGENTS HAVING CARDIOPROTECTIVE COMPONENT, FOR PROPHYLAXIS AND TREATMENT OF INFARCTION AND ANGINA PECTORIS; FOR INHIBITION OF PATHOPHYSIOLOGICAL PROCESSES ASSOCIATED WITH GENESIS OF ISCHEMICALLY INDUCED DAMAGE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-07-17 | — | — | US | disclosed |
| CN-1194976-A | Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament, and medicament comprising them | HOECHST AG (DE) | 1998-10-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | MRGPRX4 1288/4885RXRA 4265/4885RXRB 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.